跳至主要内容
临床试验/NL-OMON56804
NL-OMON56804撤回不适用

Seroprevalence Study of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV) in Patients with Plakophilin 2 (PKP2)-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) - Study of Patients with Arrhythmogenic Right Ventricular Cardiomyopathy

Tenaya Therapeutics Inc.0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
12 至 64(—)

入选标准

  • 1. Ages 14 to 65 years, inclusive, at time of consent
  • 2. Pathogenic or likely pathogenic PKP2 gene mutation
  • 3. Diagnosed with ARVC and meet 2010 Modified Task Force Criteria for ARVC
  • 4. Functioning ICD

排除标准

  • 1. Currently receiving systemic immunosuppressive therapy, cytotoxic
  • chemotherapy, immunoglobulin therapy, or monoclonal antibody therapy
  • 2. History of clinically significant liver disease, hepatitis B virus,
  • hepatitis C virus, human immunodeficiency virus, or tuberculosis infection
  • 3. Previously dosed with any investigational or approved gene therapy product
  • at any time
  • 4. Concurrent participation in another interventional clinical trial unless
  • approved by the Sponsor. Participation in a noninterventional study may be
  • allowed at the investigator*s discretion
  • 5. History of cardiac transplant

研究者

发起方
Tenaya Therapeutics Inc.

相似试验